Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that has demonstrated broad therapeutic potential across multiple oncology indications and represents a new approach to treating cancer.
Our Currently-Enrolling Clinical Trials:
Front-Line Non-Small Cell Lung Cancer (NSCLC)
Hepatocellular Carcinoma (HCC)
Bavituximab, Cotara® and I-124 PGN650 are investigational compounds. The information contained on this website is intended for clinical investigators and other qualified physicians who may be interested in enrolling patients in clinical trials.